Tempus AI CEO Eric Lefkofsky presented at the JP Morgan Healthcare Conference to discuss how the company is practising precision medicine. Rapid advances in AI have businesses in all sectors challenged to integrate new functions and increasingly covetous of proprietary data.
Tempus AI is ahead of this shift thanks to the core strategy of using diagnostic testing services to collect anonymised data directly rather than attempting to use existing frameworks. This wealth of high-quality diagnostic data, in turn, can be used to help doctors make more personalised decisions in cancer care based on the specific case rather than relying on the average outcome.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Founded in 2015, Tempus built a platform designed to turn real-world clinical information into structured, centralised, and actionable insights. It combines molecular data (such as DNA and RNA from tumours) with clinical records and outcomes, then applies analytics to surface patterns that can guide testing, diagnosis, and treatment choices. In practice, that often means helping clinicians match patients to targeted therapies or clinical trials based on the specific biology of their disease.
Its advantage today is a result of timing and scale. Sequencing has become faster and more common, hospitals are generating vast quantities of data, and treatments are increasingly focused on biomarkers, measurable signals that predict whether a given therapy is likely to work. Tempus is able to work with the large dataset it has curated and the existing platform familiar to oncologists to deliver value by improving the odds that a patient gets a therapy aligned with their tumour profile, and helping researchers learn from large populations without losing the nuance of individual cases.
This is a value proposition that is achieving impressive fiscal results. Tempus AI generated $1.59bn in revenue in 2025 with an expectation for a 25% growth year-over-year in 2026. The bulk of this revenue is driven by diagnostic testing services, which is establishing stable partnerships and rapidly increasing market share. Lefkofsky divulged that the company has worked with 55% of US-based oncologists and has been able to collect more than eight million imaging records and more than four million diagnostic samples to utilise with AI applications. It is these AI services that the company expects to give it a decisive edge in the diagnostic testing market and drive future profit.
Tempus AI is part of a larger shift as medicine becomes more data-driven, precise, and personal. Precision medicine is about turning biological and clinical details into more nuanced action. As that process keeps improving, the resulting care will be that much more personalised and should be measurably more effective.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. Sign up here to receive a comprehensive report after the conference.
